|
Trinity-Chiesi Pharmaceuticals Ltd. - United Kingdom
The UK pharmaceutical market demonstrated a growth of +3.3%. Trinity Chiesi outperformed the market growth, achieving +4% in spite of the delay in the planned launch of a key new product. This growth level is set to rapidly accelerate during 2007 with the further planned launches of new corporate pipeline products.
The most important product launch during 2006 was the long awaited Clenil Modulite®, Chiesi’s CFC-free beclometasone in September and rapidly accepted by the National Healthcare Service because of its dose equivalence to existing CFC containing products. The UK beclometasone market is around 7 million units being
prescribed annually and Trinity Chiesi has set out to gain a significant market share in 2007.
Plans are being put in place to re-model the UK affiliate in order to achieve a “fit for purpose” model to maximise the potential for the company within the new NHS structures within the respiratory market. Launch plans were also put in place for the launch of two “Special Care” new products within the therapeutic areas of Cystic Fibrosis and Ulcerative Colitis.
2007 will see Trinity Chiesi launch a number of exciting new products including a further corporate respiratory product Fostair® within the “combination product” market and to further consolidate and maximise the
market share with Clenil Modulite®. The “commercial division” of the UK affiliate will continue to thrive with the addition of two further new products. The “Special Care” hospital franchise will be strengthened further. |
